WeightControl.com: What are the main findings?
Response: The positive Phase 2 results presented at The Obesity Society’s ObesityWeek® 2022 conference show a mean body mass index (BMI) reduction of -14.5 percent at 16 weeks on setmelanotide therapy; 89 percent (16 of 18) of patients treated with setmelanotide achieved the primary endpoint with a BMI decrease greater than 5 percent at 16 weeks. Long-term data show sustained and increasing weight loss with a mean BMI reduction of -26.7 percent in patients who reached 41 weeks on therapy.
WeightControl.com: What should readers take away from your report?
Response: We have used different drugs in the past and we have not seen such a strong response to a drug intervention before. In talking with patients and their families it was very clear there was a significant change in eating behavior and their desire to eat. They were able to stay away from food for a longer time. For some of the patients that was really changing their lives. They are back to normal and not obsessed with food all the time.
WeightControl.com: What recommendations do you have for future research as a result of this work?
Response: This affects a large age range, and as a clinician I am really glad to see that we can offer this clinical research opportunity to a larger portion of our patients and that there are different tumor entities included, not just patients with craniopharyngioma, which is the most common tumor leading to hypothalamic obesity. I think it is reasonable to have a goal of quick enrollment in a Phase 3 clinical trial to further evaluate setmelanotide in hypothalamic obesity.
WeightControl.com: Is there anything else you would like to add? Any disclosures?
Response: These patients are very motivated. There is no way to treat them now. So even if we can stabilize their BMI, that is already a success because they were experiencing a steep increase in BMI before.
The Phase 2 clinical trial was sponsored by Rhythm Pharmaceuticals, Inc.
Citationd:
- Abstract resented at ObesityWeek 2022 sponsored by The Obesity SocietyPoster #176 , “Efficacy and Safety Analysis of Setmelanotide As a Novel Treatment for Hypothalamic Obesity,” on Nov. 2, 2022
2. Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA
November 1, 2022
The information on WeightControl.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on November 7, 2022 by weightcontrol